GSK Says FDA To Restrict Second-Line Maintenance Indication For Zejula

Published on November 11, 2022 07:19 AM GMT

GSK Says FDA To Restrict Second-Line Maintenance Indication For Zejula — Image source: ©2022 Kalkine Media®

Nov 11 (Reuters) - GSK plc:

* GSK PLC - GSK UPDATE: ZEJULA 2L IN US

* GSK: AT REQUEST OF FDA WILL RESTRICT SECOND-LINE MAINTENANCE INDICATION FOR ZEJULA TO ONLY PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA MUTATIONS Source text for Eikon: Further company coverage:

Reuters

Reuters -
96361 Posts
...

Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.